CROs

Lawsuit Alleges Racial Discrimination at Charles River Laboratories S.C. Facility
Lawsuit Alleges Racial Discrimination at Charles River Laboratories S.C. Facility
BioSpace
Charles River Laboratories
CROs
racial discrimination
Flag link:
CEL-SCI wins $2.9M in CRO legal battle
CEL-SCI wins $2.9M in CRO legal battle
Medical Design and Outsourcing
Cel-Sci
CROs
breach-of-contract
Flag link:
Pfizer latest pharma to join TriNetX, aims to boost real world data use
Pfizer latest pharma to join TriNetX, aims to boost real world data use
Fierce Biotech
Pfizer
clinical trials
CROs
TriNetX
Flag link:
CROs team up to develop shared tech standards
CROs team up to develop shared tech standards
Biopharma Dive
CROs
Align Clinical CRO
clinical trials
Flag link:
Biotech CEOs: Working with CROs is challenging
Biotech CEOs: Working with CROs is challenging
Biopharma Dive
biotech
CROs
R&D
Flag link:
Single-source contracting could speed drug development
Single-source contracting could speed drug development
BioPharma Dive
drug development
R&D
CMOs
CROs
Flag link:
With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica
With CRO consolidation in full swing, Catalent inks a $950M deal to acquire Cook Pharmica
Endpoints
CROs
Catalent
M&A
Cook Pharmica
R&D
Flag link:
The top 10 biopharma CROs in the world—mid-2017 edition
The top 10 biopharma CROs in the world—mid-2017 edition
Endpoints
CROs
Flag link:
Consolidation in the CRO space a plus for biopharma
Consolidation in the CRO space a plus for biopharma
BioPharma Dive
CROs
inVentiv
INC Research
Patheon
Thermofisher
Flag link:
INC Research and inVentiv Health Merge to Form CRO Worth $7.4 Billion
INC Research and inVentiv Health Merge to Form CRO Worth $7.4 Billion
Xtalks
INC Research
inVentiv
CROs
M&A
Flag link:
Takeda continues global R&D reboot with a new joint venture with PRA
Takeda continues global R&D reboot with a new joint venture with PRA
Endpoints
Takeda
R&D
CROs
PRA
Flag link:
The development landscape for Non-Alcoholic Steatohepatitis (NASH)
The development landscape for Non-Alcoholic Steatohepatitis (NASH)
BioPharma Dive
NASH
drug development
Covance
CROs
Flag link:
Takeda will transfer 300 staffers to CRO in ongoing R&D overhaul
Takeda will transfer 300 staffers to CRO in ongoing R&D overhaul
Endpoints
Takeda
reorganization
R&D
CROs
Flag link:
InVentiv Health comes on board as Pfizer's fourth CRO
InVentiv Health comes on board as Pfizer's fourth CRO
BioPharma Dive
Pfizer
inVentiv
CROs
R&D
Flag link:
CRO giant inVentiv Health could be in line for a $500M IPO
CRO giant inVentiv Health could be in line for a $500M IPO
Fierce Biotech
CROs
inVentiv
IPOs
Flag link:
CRO giant WuXi is going private in a $3.3B deal
CRO giant WuXi is going private in a $3.3B deal
Fierce Biotech
CROs
WuXi PharmaTech
China
Flag link:
Another Indian CRO in hot water, this time with the WHO
Another Indian CRO in hot water, this time with the WHO
BioPharma Dive
India
CROs
Quest
Flag link:
Parexel axing 850 jobs in big reorg
Parexel axing 850 jobs in big reorg
BioPharma Dive
Parexel
reorganization
layoffs
CROs
Flag link:
Biopharma's R&D budgets stay about flat amid global cuts
Biopharma's R&D budgets stay about flat amid global cuts
Fierce Biotech
R&D
CROs
biotech
Flag link:
'Fastest way to biosimilar approval? As the CRO flies,' says industry group
'Fastest way to biosimilar approval? As the CRO flies,' says industry group
Bio-Pharma Reporter
biosimilars
CROs
drug approvals
Flag link:

Pages